Standardized incidence ratios and absolute excess risks according to NHL treatment: additional treatment increases risk of cardiovascular disease
Event, treatment . | No. of patients* . | No. observed . | No. expected . | SIR (95% CI) . | AER per 10 000 person-years . |
|---|---|---|---|---|---|
| Chronic heart failure | |||||
| After salvage (any type) | 225 | 38 | 4.3 | 8.8 (6.3-12.1) | 346 |
| After first-line treatment only | 216 | 26 | 7.7 | 3.4 (2.2-4.9) | 120 |
| Only chemotherapy | 162 | 20 | 6.4 | 3.1 (1.9-4.8) | 127 |
| Chemotherapy and RT | 38 | 4 | 1.1 | 3.6 (1.0-9.8) | 120 |
| Chemotherapy and transplantation | 13 | 1 | 0.1 | 7.1 (0.2-39.8) | 81 |
| Chemotherapy, RT, and transplantation | 12 | 1 | 0.1 | 12.5 (0.3-69.7) | 83 |
| Myocardial infarction | |||||
| After salvage (any type) | 241 | 10 | 6.8 | 1.5 (0.7-2.7) | 29 |
| After first-line treatment only | 235 | 7 | 9.0 | 0.8 (0.3-1.6) | 13 |
| Only chemotherapy | 170 | 6 | 6.5 | 0.9 (0.3-2.0) | 5 |
| Chemotherapy and RT | 40 | 1 | 1.8 | 0.6 (0.1-3.1) | 33 |
| Chemotherapy and transplantation | 13 | 0 | 0.5 | 0 | 0 |
| Chemotherapy, RT, and transplantation | 12 | 0 | 0.2 | 0 | 0 |
| Stroke | |||||
| After salvage (any type) | 225 | 4 | 3.2 | 1.3 (0.3-3.3) | 12 |
| After first-line treatment only | 216 | 7 | 5.1 | 1.4 (0.6-2.8) | 8 |
| Only chemotherapy | 135 | 2 | 3.4 | 0.6 (0.1-2.1) | –13 |
| Chemotherapy and RT | 56 | 5 | 1.5 | 3.3 (1.1-7.8) | 145 |
| Chemotherapy and transplantation | 15 | 0 | 0.1 | 0 | 0 |
| Chemotherapy, RT, and transplantation | 10 | 0 | 0.1 | 0 | 0 |
Event, treatment . | No. of patients* . | No. observed . | No. expected . | SIR (95% CI) . | AER per 10 000 person-years . |
|---|---|---|---|---|---|
| Chronic heart failure | |||||
| After salvage (any type) | 225 | 38 | 4.3 | 8.8 (6.3-12.1) | 346 |
| After first-line treatment only | 216 | 26 | 7.7 | 3.4 (2.2-4.9) | 120 |
| Only chemotherapy | 162 | 20 | 6.4 | 3.1 (1.9-4.8) | 127 |
| Chemotherapy and RT | 38 | 4 | 1.1 | 3.6 (1.0-9.8) | 120 |
| Chemotherapy and transplantation | 13 | 1 | 0.1 | 7.1 (0.2-39.8) | 81 |
| Chemotherapy, RT, and transplantation | 12 | 1 | 0.1 | 12.5 (0.3-69.7) | 83 |
| Myocardial infarction | |||||
| After salvage (any type) | 241 | 10 | 6.8 | 1.5 (0.7-2.7) | 29 |
| After first-line treatment only | 235 | 7 | 9.0 | 0.8 (0.3-1.6) | 13 |
| Only chemotherapy | 170 | 6 | 6.5 | 0.9 (0.3-2.0) | 5 |
| Chemotherapy and RT | 40 | 1 | 1.8 | 0.6 (0.1-3.1) | 33 |
| Chemotherapy and transplantation | 13 | 0 | 0.5 | 0 | 0 |
| Chemotherapy, RT, and transplantation | 12 | 0 | 0.2 | 0 | 0 |
| Stroke | |||||
| After salvage (any type) | 225 | 4 | 3.2 | 1.3 (0.3-3.3) | 12 |
| After first-line treatment only | 216 | 7 | 5.1 | 1.4 (0.6-2.8) | 8 |
| Only chemotherapy | 135 | 2 | 3.4 | 0.6 (0.1-2.1) | –13 |
| Chemotherapy and RT | 56 | 5 | 1.5 | 3.3 (1.1-7.8) | 145 |
| Chemotherapy and transplantation | 15 | 0 | 0.1 | 0 | 0 |
| Chemotherapy, RT, and transplantation | 10 | 0 | 0.1 | 0 | 0 |
Comparison in 476 patients for myocardial infarction (1980-2000) and in 441 patients for chronic heart failure and stroke (1985-2000)